India Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Dosage Form (Tablets, Injectables), By Manufacturing Type (In-house, Contract), By Therapeutic Category (Endrocrinology, Cardiovascular), And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
India Pharmaceutical Manufacturing Market Growth & Trends
The India pharmaceutical manufacturing market size is expected to reach USD 35.38 billion by 2030, growing at a CAGR of 10.5%, according to a new study by Grand View Research, Inc. The growth of the market is attributed to the rapid adoption of advanced technologies in clinical research, a rise in diversity & prevalence of diseases, and increased outsourcing activities due to intensified R&D efforts. Moreover, several initiatives are taken up by public and government organizations to enhance R&D attempts and further boost market growth. For instance, in October 2021, the Department of Pharmaceuticals in India introduced a new policy to reduce the approval time for innovative products by at least 50% within the next 2 years, promoting R&D activities within the country.
The increasing prevalence of cancer, cardiovascular disease, diabetes, and infectious diseases is expected to be a high-impact-rendering driver for the market over the next 6 years. The increasing shift of individuals towards unhealthy lifestyles such as smoking, increasing incidence of obesity, and more individuals experiencing dietary irregularities is the major cause of increased prevalence of cardiovascular diseases among the population. Moreover, the prevalence of diabetes across the country is increasing, thereby surging the patient pool for associated pharmaceuticals. Moreover, healthcare has grown to be one of the most important areas of the Indian economy, both in revenue and employment.
A continuous increase in clinical trials of pharmaceutical products is expected to create numerous opportunities for market growth in the coming years. In 2020, India's contribution to global clinical trial activity reached 8.3%, marking an increase compared to the previous decade's average of 6.2%. In oncology, India accounted for 9.0% of the share in 2020, a decrease from the 5-year and 10-year averages of 12.4% and 13.4% respectively. For respiratory-related trials, India held an 8.7% share in 2020, surpassing the 5-year and 10-year averages of 6.1% & 6.5%, respectively. In metabolic disorders, India's share was 8.5% in 2020, lower than the 5-year average of 13.2% and the 10-year average of 14.1%.
India is the world's third-largest producer of pharmaceuticals by volume and the twelfth-largest producer by value. With a 20% volume share of worldwide generic medication supply, the sector leads the globe in vaccine production and sales, accounting for 60% of the global market. From April 2000 to December 2022, total FDI in the pharmaceutical sector was estimated at USD 21.22 billion. In addition, the Indian pharmaceutical industry is worth over USD 50 billion, with exports accounting for over USD 25 billion. India accounts for over 20% of global generic medicine exports. Thus, increasing pharmaceutical R&D spending is expected to propel the market over the projected timeframe.
Key players operating in the market are developing innovative technologies and services to overcome the challenges in pharmaceutical manufacturing. For instance, in September 2023, Akums Drugs and Pharmaceuticals Limited announced the launch of Tamsulosin + Tadalafil capsule, a combination therapy approved by DCGI in the Indian market for the management of lower urinary tract symptoms and erectile dysfunction in men. The company announced its launch with an aim to expand its urology segment.
India Pharmaceutical Manufacturing Market Report Highlights
India Pharmaceutical Manufacturing Market Growth & Trends
The India pharmaceutical manufacturing market size is expected to reach USD 35.38 billion by 2030, growing at a CAGR of 10.5%, according to a new study by Grand View Research, Inc. The growth of the market is attributed to the rapid adoption of advanced technologies in clinical research, a rise in diversity & prevalence of diseases, and increased outsourcing activities due to intensified R&D efforts. Moreover, several initiatives are taken up by public and government organizations to enhance R&D attempts and further boost market growth. For instance, in October 2021, the Department of Pharmaceuticals in India introduced a new policy to reduce the approval time for innovative products by at least 50% within the next 2 years, promoting R&D activities within the country.
The increasing prevalence of cancer, cardiovascular disease, diabetes, and infectious diseases is expected to be a high-impact-rendering driver for the market over the next 6 years. The increasing shift of individuals towards unhealthy lifestyles such as smoking, increasing incidence of obesity, and more individuals experiencing dietary irregularities is the major cause of increased prevalence of cardiovascular diseases among the population. Moreover, the prevalence of diabetes across the country is increasing, thereby surging the patient pool for associated pharmaceuticals. Moreover, healthcare has grown to be one of the most important areas of the Indian economy, both in revenue and employment.
A continuous increase in clinical trials of pharmaceutical products is expected to create numerous opportunities for market growth in the coming years. In 2020, India's contribution to global clinical trial activity reached 8.3%, marking an increase compared to the previous decade's average of 6.2%. In oncology, India accounted for 9.0% of the share in 2020, a decrease from the 5-year and 10-year averages of 12.4% and 13.4% respectively. For respiratory-related trials, India held an 8.7% share in 2020, surpassing the 5-year and 10-year averages of 6.1% & 6.5%, respectively. In metabolic disorders, India's share was 8.5% in 2020, lower than the 5-year average of 13.2% and the 10-year average of 14.1%.
India is the world's third-largest producer of pharmaceuticals by volume and the twelfth-largest producer by value. With a 20% volume share of worldwide generic medication supply, the sector leads the globe in vaccine production and sales, accounting for 60% of the global market. From April 2000 to December 2022, total FDI in the pharmaceutical sector was estimated at USD 21.22 billion. In addition, the Indian pharmaceutical industry is worth over USD 50 billion, with exports accounting for over USD 25 billion. India accounts for over 20% of global generic medicine exports. Thus, increasing pharmaceutical R&D spending is expected to propel the market over the projected timeframe.
Key players operating in the market are developing innovative technologies and services to overcome the challenges in pharmaceutical manufacturing. For instance, in September 2023, Akums Drugs and Pharmaceuticals Limited announced the launch of Tamsulosin + Tadalafil capsule, a combination therapy approved by DCGI in the Indian market for the management of lower urinary tract symptoms and erectile dysfunction in men. The company announced its launch with an aim to expand its urology segment.
India Pharmaceutical Manufacturing Market Report Highlights
- Based on dosage form, tablet segment dominated the market and is anticipated to grow at fastest growth over the forecast period owing to the widespread availability of tablet-based products in various formulations, including film-coated, enteric-coated, orally disintegrating, and effervescent tablets.
- The contract manufacturing segment dominated the market attributed to benefits associated with outsourced services that help enhance the efficiency of manufacturing procedures.
- Based on therapeutic category, the cardiovascular segment is expected to grow at fastest rate owing to the rising prevalence of cardiovascular diseases and an increasing investment in R&D for the development of innovative drugs.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation
1.1.1 Market Definitions
1.1.2 Estimates and Forecast Timeline
1.2 Objectives
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 GVR’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
1.8 List of Secondary Sources
1.9 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Dosage Form and Manufacturing Type Snapshot
2.3 Therapeutic Category Segment Snapshot
2.4 Competitive Landscape Snapshot
CHAPTER 3 INDIAN PHARMACEUTICAL MANUFACTURING MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Global Pharmaceutical Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Pharmaceutical R&D Spending
3.2.1.2 Advancements in Pharmaceutical Manufacturing Technologies
3.2.1.3 Rising Geriatric Population and Prevalence of Chronic Disorders
3.2.2 Market Restraint Analysis
3.2.2.1 Challenges in Pharma Supply Chain
3.2.2.2 Inadequate Training and Motivation for Research and Innovations Efforts
3.3 Market Analysis Tools
3.3.1 Industry Analysis: Porter's Five Forces
3.3.2 Macroeconomic Analysis
3.4 Current & Future Market Opportunity Analysis
3.4.1 Current Opportunity Analysis
3.4.1.1 Increase in Clinical Trials
3.4.1.2 Increasing Investment and Funding in Pharmaceutical IT
3.4.2 The Future of Indian Manufacturing
3.5 Queries/Request Raised by CMOs
3.6 List of Key 5 Solid Dosage Drugs for Each Therapeutic Area
CHAPTER 4 INDIA PHARMACEUTICAL MANUFACTURING MARKET - SEGMENT ANALYSIS, BY DOSAGE FORM, 2018 - 2030 (USD MILLION)
4.1 India Pharmaceutical Manufacturing Market: Dosage Form Movement Analysis
4.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Dosage Form (USD Million)
4.3 Penetration & Growth Prospect Mapping for Dosage Form, 2023
4.3.1 Tablets
4.3.1.1 Tablets Market, 2018 - 2030 (USD Million)
4.3.2 Capsules
4.3.2.1 Capsules Market, 2018 - 2030 (USD Million)
4.3.2.2.1 Soft Gelatin Capsule
4.3.2.2.1.1 Soft Gelatin Capsules Market, 2018 - 2030 (USD Million)
4.3.2.3.1 Hard Gelatin Capsules
4.3.1.3.1.1 Hard Gelatin Capsules Market, 2018 - 2030 (USD Million)
4.3.2.4.1 Others
4.3.2.4.1.1 Others Market, 2018 - 2030 (USD Million)
4.3.3 Injectables
4.3.3.1 Injectables Market, 2018 - 2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 INDIA PHARMACEUTICAL MANUFACTURING MARKET - SEGMENT ANALYSIS, BY MANUFACTURING TYPE, 2018 - 2030 (USD MILLION)
5.1 India Pharmaceutical Manufacturing Market: Manufacturing Type Movement Analysis
5.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Manufacturing Type (USD Million)
5.3 Penetration & Growth Prospect Mapping for Manufacturing Type, 2023
5.3.1 IN-HOUSE MANUFACTURING
5.3.1.1 In-house MAnufacturing Market, 2018 - 2030 (USD Million)
5.3.2 CONTRACT MANUFACTURING
5.3.2.1 Contract Manufacturing Market, 2018 - 2030 (USD Million)
CHAPTER 6 INDIA PHARMACEUTICAL MANUFACTURING MARKET - SEGMENT ANALYSIS, BY THERAPEUTIC CATEGORY, 2018 - 2030 (USD MILLION)
6.1 India Pharmaceutical Manufacturing Market: Therapeutic Category Movement Analysis
6.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Therapeutic Category (USD Million)
6.3 Penetration & Growth Prospect Mapping for Therapeutic Category, 2023
6.4 Endocrinology
6.4.1 Canagliflozin
6.4.1.1 Approval
6.4.1.2 Patent Expiry
6.4.1.3 Available Combinations
6.4.1.4 Countries The Drug is Available in
6.4.1.5 Trends
6.4.2 Empagliflozin
6.4.2.1 Approval
6.4.2.2 Patent Expiry
6.4.2.3 Available Combinations
6.4.2.4 Countries Drug Available in
6.4.2.5 Trends
6.4.3 Semaglutide
6.4.3.1 Approval
6.4.3.2 Patent Expiry
6.4.3.3 Available Combinations
6.4.3.4 Countries Drug Available in
6.4.3.5 Trends
6.4.4 Tirzepatide
6.4.4.1 Approval
6.4.4.2 Patent Expiry
6.4.4.3 Available Combinations
6.4.4.4 Countries Drug Available in
6.4.4.5 Trends
6.4.5 Linagliptin
6.4.5.1 Approval
6.4.5.2 Patent Expiry
6.4.5.3 Available Combinations
6.4.5.4 Countries Drug Available in
6.4.5.5 Trends
6.4.6 Alogliptin
6.4.6.1 Approval
6.4.6.2 Patent Expiry
6.4.6.3 Available Combinations
6.4.7 Trelagliptin
6.4.8 Myo-Inositol
6.5 Cardiovascular
6.5.1 Treprostinil
6.5.1.1 Approval
6.5.1.2 Patent Expiry
6.5.1.3 Available Combinations
6.5.1.4 Trends
6.5.2 Azilsartan
6.5.2.1 Approval
6.5.2.2 Patent Expiry
6.5.2.3 Available Combinations
6.5.3 Azilsartan+Amlodipine
6.5.4 Amlodipine + Lisinopril
6.5.5 Sparsentan
6.5.5.1 Approval
6.5.5.2 Patent Expiry
6.5.5.3 Available Combinations
6.5.6 Esaxerenone
6.5.6.1 Approval
6.5.6.2 Available Combinations
6.6 CNS
6.6.1 Cariprazine
6.6.1.1 Approval
6.6.1.2 Patent Expiry
6.6.1.3 Available Combinations
6.6.1.4 Countries Drug Available in
6.6.1.5 Trends
6.6.2 Brexpiprazole
6.6.2.1 Approval
6.6.2.2 Patent Expiry
6.6.2.3 Available Combinations
6.6.2.4 Trends
6.6.3 Lisdexamfetamine
6.6.3.1 Approval
6.6.3.2 Patent Expiry
6.6.3.3 Available Combinations
6.6.3.4 Trends
6.6.4 Vortioxetine
6.6.4.1 Approval
6.6.4.2 Patent Expiry
6.6.4.3 Available Combinations
6.6.4.4 Countries Drug Available in
6.6.4.5 Trends
6.6.5 Mirogabalin Besylate
6.6.6 Lasmiditan
6.6.6.1 Approval
6.6.6.2 Patent Expiry
6.6.6.3 Available Combinations
6.6.6.4 Trends
6.6.7 Siponimod
6.6.7.1 Approval
6.6.7.2 Patent Expiry
6.6.7.3 Available Combinations
6.6.7.4 Trends
6.7 Analgesics
6.7.1 Ibuprofen+Famotidine
6.7.2 Upadacitinib
6.7.2.1 Approval
6.7.2.2 Patent Expiry
6.7.2.3 Available Combinations
6.7.2.4 Countries Drug Available in
6.7.2.5 Trends
6.8 Antacid
6.8.1 Pantoprazole Gastro Resistant
6.8.1.1 Approval
6.8.1.2 Patent Expiry
6.9 Antibiotic
6.9.1 Doxycycline
6.9.1.1 Approval
6.9.1.2 Patent Expiry
6.9.1.3 Available Combinations
6.9.2 Tedizolid
6.10 Antifungal
6.10.1 Posaconazole
6.10.1.1 Approval
6.10.1.2 Patent Expiry
6.10.1.3 Available Combinations
6.11 Antiprotozoal
6.11.1 Nitazoxanide
6.11.1.1 Approval
6.11.1.2 Patent Expiry
6.11.1.3 Available Combinations
6.12 Hematology
6.12.1 Lenalidomide
6.12.1.1 Approval
6.12.1.2 Patent Expiry
6.12.1.3 Available Combinations
6.12.1.4 Trends
6.12.2 Daprodustat
6.12.2.1 Approval
6.12.2.2 Patent Expiry
6.12.2.3 Available Combinations
6.12.2.4 Trends
6.12.3 Roxadustat
6.12.3.1 Approval
6.12.3.2 Available Combinations
6.12.3.3 Countries Drug Available in
6.12.4 Edoxaban
6.12.4.1 Approval
6.12.4.2 Patent Expiry
6.12.4.3 Available Combinations
6.12.4.4 Countries Drug Available in
6.12.4.5 Trends
6.12.5 Avatrombopag
6.12.5.1 Approval
6.12.5.2 Available Combinations
6.12.5.3 Trends
6.13 Others
6.13.1 Linaclotide
6.13.1.1 Approval
6.13.1.2 Patent Expiry
6.13.1.3 Available Combinations
6.13.1.4 Trends
6.13.2 Apremilast
6.13.2.1 Approval
6.13.2.2 Patent Expiry
6.13.2.3 Available Combinations
6.13.2.4 Trends
6.13.3 Tegoprazan
6.13.4 Suvorexant
6.13.4.1 Approval
6.13.4.2 Patent Expiry
6.13.4.3 Available Combinations
6.13.4.4 Trends
6.13.5 Vonoprazan
6.13.5.1 Approval
6.13.5.2 Patent Expiry
6.13.5.3 Available Combinations
6.13.5.4 Trends
6.13.6 Rolapitant
6.13.6.1 Approval
6.13.6.2 Patent Expiry
6.13.6.3 Available Combinations
6.13.7 Elagolix
6.13.7.1 Approval
6.13.7.2 Patent Expiry
6.13.7.3 Available Combinations
6.13.7.4 Trends
CHAPTER 7 GLOBAL ONCOLOGY PHARMACEUTICAL MANUFACTURING MARKET
7.1 List of Cancer Molecules Going Off Patent Between 2023 and 2030
7.2 Global Overview
7.3 Market Opportunities, By Type of Cancer
CHAPTER 8 INDIA INJECTABLES PHARMACEUTICAL MANUFACTURING MARKET
8.1 Complete India Market Overview
8.2 Exports in Injectable Formulation
8.2.1 By Therapeutic Category
8.2.1.1 Endocrinology
8.2.1.2 Cardiovascular
8.2.1.3 CNS
8.2.1.4 Analgesics
8.2.1.5 Antacid
8.2.1.6 Antibiotic
8.2.1.7 Antifungal
8.2.1.8 Antiprotozoal
8.2.1.9 Hematology
8.2.1.10 Others
8.2.2 By Dosage Form
8.2.2.1 Intravenous
8.2.2.2 Subcutaneous
8.2.2.3 Intramuscular
8.2.2.4 Others
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Participants’ Overview
9.2 Financial Performance
9.3 Public Players Financial Overview
9.3.1 Alkem Laboratories Ltd.
9.3.1.1 Alkem's Performance in Key Therapeutic Segments
9.3.1.2 Performance of Alkem’s Top 10 Brands
9.3.2 Sun Pharmaceutical Industries Ltd.
9.3.2.1 India Business Therapeutic Revenue Break-Up
9.3.2.2 Business-Wise Revenue Share
9.3.3 Ajanta Pharma Ltd.
9.3.3.1 Focused Presence in Key Therapy Areas
9.3.4 Cipla Inc.
9.3.4.1 Manufacturing capabilities highlights (in million units) FY 2022-23
9.3.4.2 Global Presence
9.3.4.3 Branded Prescription Business
9.3.4.4 API Manufacturing Capability
9.3.5 Eris Lifesciences
9.3.5.1 Eris Lifesciences Performance in Key Therapeutic Segments
9.3.6 Lupin
9.3.6.1 Lupin’s Therapy-Wise Ranking
9.3.7 Glenmark Pharmaceuticals Ltd.
9.3.7.1 Revenue Distribution by Geographies
9.3.7.2 Top Brands of Glenmark in Top 300 of IPM
9.3.8 Torrent Pharmaceuticals Ltd.
9.3.8.1 Revenue Distribution by Geographies
9.4 Participant Categorization
9.4.1 Key Company Market Share Analysis
9.4.2 Strategy Mapping
9.4.2.1 Acquisition
9.4.2.2 Partnership & Collaborations
9.4.2.3 Product Launches
9.4.2.4 Expansion
9.4.2.5 Others (Investment, Divestment, Market Penetration, Funding, & Approval)
9.5 List of Key CMOs
CHAPTER 10 CONCLUSION
1.1 Market Segmentation
1.1.1 Market Definitions
1.1.2 Estimates and Forecast Timeline
1.2 Objectives
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 GVR’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details of Primary Research
1.5 Information or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
1.8 List of Secondary Sources
1.9 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Dosage Form and Manufacturing Type Snapshot
2.3 Therapeutic Category Segment Snapshot
2.4 Competitive Landscape Snapshot
CHAPTER 3 INDIAN PHARMACEUTICAL MANUFACTURING MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Global Pharmaceutical Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Pharmaceutical R&D Spending
3.2.1.2 Advancements in Pharmaceutical Manufacturing Technologies
3.2.1.3 Rising Geriatric Population and Prevalence of Chronic Disorders
3.2.2 Market Restraint Analysis
3.2.2.1 Challenges in Pharma Supply Chain
3.2.2.2 Inadequate Training and Motivation for Research and Innovations Efforts
3.3 Market Analysis Tools
3.3.1 Industry Analysis: Porter's Five Forces
3.3.2 Macroeconomic Analysis
3.4 Current & Future Market Opportunity Analysis
3.4.1 Current Opportunity Analysis
3.4.1.1 Increase in Clinical Trials
3.4.1.2 Increasing Investment and Funding in Pharmaceutical IT
3.4.2 The Future of Indian Manufacturing
3.5 Queries/Request Raised by CMOs
3.6 List of Key 5 Solid Dosage Drugs for Each Therapeutic Area
CHAPTER 4 INDIA PHARMACEUTICAL MANUFACTURING MARKET - SEGMENT ANALYSIS, BY DOSAGE FORM, 2018 - 2030 (USD MILLION)
4.1 India Pharmaceutical Manufacturing Market: Dosage Form Movement Analysis
4.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Dosage Form (USD Million)
4.3 Penetration & Growth Prospect Mapping for Dosage Form, 2023
4.3.1 Tablets
4.3.1.1 Tablets Market, 2018 - 2030 (USD Million)
4.3.2 Capsules
4.3.2.1 Capsules Market, 2018 - 2030 (USD Million)
4.3.2.2.1 Soft Gelatin Capsule
4.3.2.2.1.1 Soft Gelatin Capsules Market, 2018 - 2030 (USD Million)
4.3.2.3.1 Hard Gelatin Capsules
4.3.1.3.1.1 Hard Gelatin Capsules Market, 2018 - 2030 (USD Million)
4.3.2.4.1 Others
4.3.2.4.1.1 Others Market, 2018 - 2030 (USD Million)
4.3.3 Injectables
4.3.3.1 Injectables Market, 2018 - 2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 INDIA PHARMACEUTICAL MANUFACTURING MARKET - SEGMENT ANALYSIS, BY MANUFACTURING TYPE, 2018 - 2030 (USD MILLION)
5.1 India Pharmaceutical Manufacturing Market: Manufacturing Type Movement Analysis
5.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Manufacturing Type (USD Million)
5.3 Penetration & Growth Prospect Mapping for Manufacturing Type, 2023
5.3.1 IN-HOUSE MANUFACTURING
5.3.1.1 In-house MAnufacturing Market, 2018 - 2030 (USD Million)
5.3.2 CONTRACT MANUFACTURING
5.3.2.1 Contract Manufacturing Market, 2018 - 2030 (USD Million)
CHAPTER 6 INDIA PHARMACEUTICAL MANUFACTURING MARKET - SEGMENT ANALYSIS, BY THERAPEUTIC CATEGORY, 2018 - 2030 (USD MILLION)
6.1 India Pharmaceutical Manufacturing Market: Therapeutic Category Movement Analysis
6.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Therapeutic Category (USD Million)
6.3 Penetration & Growth Prospect Mapping for Therapeutic Category, 2023
6.4 Endocrinology
6.4.1 Canagliflozin
6.4.1.1 Approval
6.4.1.2 Patent Expiry
6.4.1.3 Available Combinations
6.4.1.4 Countries The Drug is Available in
6.4.1.5 Trends
6.4.2 Empagliflozin
6.4.2.1 Approval
6.4.2.2 Patent Expiry
6.4.2.3 Available Combinations
6.4.2.4 Countries Drug Available in
6.4.2.5 Trends
6.4.3 Semaglutide
6.4.3.1 Approval
6.4.3.2 Patent Expiry
6.4.3.3 Available Combinations
6.4.3.4 Countries Drug Available in
6.4.3.5 Trends
6.4.4 Tirzepatide
6.4.4.1 Approval
6.4.4.2 Patent Expiry
6.4.4.3 Available Combinations
6.4.4.4 Countries Drug Available in
6.4.4.5 Trends
6.4.5 Linagliptin
6.4.5.1 Approval
6.4.5.2 Patent Expiry
6.4.5.3 Available Combinations
6.4.5.4 Countries Drug Available in
6.4.5.5 Trends
6.4.6 Alogliptin
6.4.6.1 Approval
6.4.6.2 Patent Expiry
6.4.6.3 Available Combinations
6.4.7 Trelagliptin
6.4.8 Myo-Inositol
6.5 Cardiovascular
6.5.1 Treprostinil
6.5.1.1 Approval
6.5.1.2 Patent Expiry
6.5.1.3 Available Combinations
6.5.1.4 Trends
6.5.2 Azilsartan
6.5.2.1 Approval
6.5.2.2 Patent Expiry
6.5.2.3 Available Combinations
6.5.3 Azilsartan+Amlodipine
6.5.4 Amlodipine + Lisinopril
6.5.5 Sparsentan
6.5.5.1 Approval
6.5.5.2 Patent Expiry
6.5.5.3 Available Combinations
6.5.6 Esaxerenone
6.5.6.1 Approval
6.5.6.2 Available Combinations
6.6 CNS
6.6.1 Cariprazine
6.6.1.1 Approval
6.6.1.2 Patent Expiry
6.6.1.3 Available Combinations
6.6.1.4 Countries Drug Available in
6.6.1.5 Trends
6.6.2 Brexpiprazole
6.6.2.1 Approval
6.6.2.2 Patent Expiry
6.6.2.3 Available Combinations
6.6.2.4 Trends
6.6.3 Lisdexamfetamine
6.6.3.1 Approval
6.6.3.2 Patent Expiry
6.6.3.3 Available Combinations
6.6.3.4 Trends
6.6.4 Vortioxetine
6.6.4.1 Approval
6.6.4.2 Patent Expiry
6.6.4.3 Available Combinations
6.6.4.4 Countries Drug Available in
6.6.4.5 Trends
6.6.5 Mirogabalin Besylate
6.6.6 Lasmiditan
6.6.6.1 Approval
6.6.6.2 Patent Expiry
6.6.6.3 Available Combinations
6.6.6.4 Trends
6.6.7 Siponimod
6.6.7.1 Approval
6.6.7.2 Patent Expiry
6.6.7.3 Available Combinations
6.6.7.4 Trends
6.7 Analgesics
6.7.1 Ibuprofen+Famotidine
6.7.2 Upadacitinib
6.7.2.1 Approval
6.7.2.2 Patent Expiry
6.7.2.3 Available Combinations
6.7.2.4 Countries Drug Available in
6.7.2.5 Trends
6.8 Antacid
6.8.1 Pantoprazole Gastro Resistant
6.8.1.1 Approval
6.8.1.2 Patent Expiry
6.9 Antibiotic
6.9.1 Doxycycline
6.9.1.1 Approval
6.9.1.2 Patent Expiry
6.9.1.3 Available Combinations
6.9.2 Tedizolid
6.10 Antifungal
6.10.1 Posaconazole
6.10.1.1 Approval
6.10.1.2 Patent Expiry
6.10.1.3 Available Combinations
6.11 Antiprotozoal
6.11.1 Nitazoxanide
6.11.1.1 Approval
6.11.1.2 Patent Expiry
6.11.1.3 Available Combinations
6.12 Hematology
6.12.1 Lenalidomide
6.12.1.1 Approval
6.12.1.2 Patent Expiry
6.12.1.3 Available Combinations
6.12.1.4 Trends
6.12.2 Daprodustat
6.12.2.1 Approval
6.12.2.2 Patent Expiry
6.12.2.3 Available Combinations
6.12.2.4 Trends
6.12.3 Roxadustat
6.12.3.1 Approval
6.12.3.2 Available Combinations
6.12.3.3 Countries Drug Available in
6.12.4 Edoxaban
6.12.4.1 Approval
6.12.4.2 Patent Expiry
6.12.4.3 Available Combinations
6.12.4.4 Countries Drug Available in
6.12.4.5 Trends
6.12.5 Avatrombopag
6.12.5.1 Approval
6.12.5.2 Available Combinations
6.12.5.3 Trends
6.13 Others
6.13.1 Linaclotide
6.13.1.1 Approval
6.13.1.2 Patent Expiry
6.13.1.3 Available Combinations
6.13.1.4 Trends
6.13.2 Apremilast
6.13.2.1 Approval
6.13.2.2 Patent Expiry
6.13.2.3 Available Combinations
6.13.2.4 Trends
6.13.3 Tegoprazan
6.13.4 Suvorexant
6.13.4.1 Approval
6.13.4.2 Patent Expiry
6.13.4.3 Available Combinations
6.13.4.4 Trends
6.13.5 Vonoprazan
6.13.5.1 Approval
6.13.5.2 Patent Expiry
6.13.5.3 Available Combinations
6.13.5.4 Trends
6.13.6 Rolapitant
6.13.6.1 Approval
6.13.6.2 Patent Expiry
6.13.6.3 Available Combinations
6.13.7 Elagolix
6.13.7.1 Approval
6.13.7.2 Patent Expiry
6.13.7.3 Available Combinations
6.13.7.4 Trends
CHAPTER 7 GLOBAL ONCOLOGY PHARMACEUTICAL MANUFACTURING MARKET
7.1 List of Cancer Molecules Going Off Patent Between 2023 and 2030
7.2 Global Overview
7.3 Market Opportunities, By Type of Cancer
CHAPTER 8 INDIA INJECTABLES PHARMACEUTICAL MANUFACTURING MARKET
8.1 Complete India Market Overview
8.2 Exports in Injectable Formulation
8.2.1 By Therapeutic Category
8.2.1.1 Endocrinology
8.2.1.2 Cardiovascular
8.2.1.3 CNS
8.2.1.4 Analgesics
8.2.1.5 Antacid
8.2.1.6 Antibiotic
8.2.1.7 Antifungal
8.2.1.8 Antiprotozoal
8.2.1.9 Hematology
8.2.1.10 Others
8.2.2 By Dosage Form
8.2.2.1 Intravenous
8.2.2.2 Subcutaneous
8.2.2.3 Intramuscular
8.2.2.4 Others
CHAPTER 9 COMPETITIVE LANDSCAPE
9.1 Participants’ Overview
9.2 Financial Performance
9.3 Public Players Financial Overview
9.3.1 Alkem Laboratories Ltd.
9.3.1.1 Alkem's Performance in Key Therapeutic Segments
9.3.1.2 Performance of Alkem’s Top 10 Brands
9.3.2 Sun Pharmaceutical Industries Ltd.
9.3.2.1 India Business Therapeutic Revenue Break-Up
9.3.2.2 Business-Wise Revenue Share
9.3.3 Ajanta Pharma Ltd.
9.3.3.1 Focused Presence in Key Therapy Areas
9.3.4 Cipla Inc.
9.3.4.1 Manufacturing capabilities highlights (in million units) FY 2022-23
9.3.4.2 Global Presence
9.3.4.3 Branded Prescription Business
9.3.4.4 API Manufacturing Capability
9.3.5 Eris Lifesciences
9.3.5.1 Eris Lifesciences Performance in Key Therapeutic Segments
9.3.6 Lupin
9.3.6.1 Lupin’s Therapy-Wise Ranking
9.3.7 Glenmark Pharmaceuticals Ltd.
9.3.7.1 Revenue Distribution by Geographies
9.3.7.2 Top Brands of Glenmark in Top 300 of IPM
9.3.8 Torrent Pharmaceuticals Ltd.
9.3.8.1 Revenue Distribution by Geographies
9.4 Participant Categorization
9.4.1 Key Company Market Share Analysis
9.4.2 Strategy Mapping
9.4.2.1 Acquisition
9.4.2.2 Partnership & Collaborations
9.4.2.3 Product Launches
9.4.2.4 Expansion
9.4.2.5 Others (Investment, Divestment, Market Penetration, Funding, & Approval)
9.5 List of Key CMOs
CHAPTER 10 CONCLUSION
LIST OF TABLES
Table 1 List of abbreviation
Table 2 List of data points generally requested by the Indian CMOs from Grand View Research Inc.
Table 3 India pharmaceutical manufacturing market revenue estimates and forecast, by dosage form, 2018 - 2030 (USD Million)
Table 4 India pharmaceutical manufacturing market revenue estimates and forecast, by manufacturing type, 2018 - 2030 (USD Million)
Table 5 India pharmaceutical manufacturing market revenue estimates and forecast, by therapeutic category, 2018 - 2030 (USD Million)
Table 6 Patent expiry data for approved formulation:
Table 7 Brand name/prescription products:
Table 8 Combinations products:
Table 9 Patent expiry data for approved formulation:
Table 10 Brand name/prescription products:
Table 11 Combinations products:
Table 12 Patent expiry data for approved formulation:
Table 13 Brand name/prescription products:
Table 14 Patent expiry data for approved formulation:
Table 15 Brand name/prescription products:
Table 16 Patent expiry data for approved formulation:
Table 17 Brand name/prescription products:
Table 18 Combinations products:
Table 19 Patent expiry data for approved formulation:
Table 20 Brand name/prescription products:
Table 21 Generic products:
Table 22 Combinations products:
Table 23 Patent expiry data for approved formulation:
Table 24 Brand name/prescription products:
Table 25 Generic products:
Table 26 Combination Products:
Table 27 Patent expiry data for approved formulation:
Table 28 Brand name/prescription products:
Table 29 Combinations products:
Table 30 Patent expiry data for approved formulation:
Table 31 Brand name/prescription products:
Table 32 Brand name/prescription products:
Table 33 Patent expiry data for approved formulation:
Table 34 Brand name/prescription products:
Table 35 Combinations products:
Table 36 Patent expiry data for approved formulation:
Table 37 Brand name/prescription products:
Table 38 Generic products:
Table 39 Combinations products:
Table 40 Patent expiry data for approved formulation:
Table 41 Brand name/prescription products:
Table 42 Generic products:
Table 43 Patent expiry data for approved formulation:
Table 44 Brand name/prescription products:
Table 45 Patent expiry data for approved formulation:
Table 46 Brand name/prescription products:
Table 47 Patent expiry data for approved formulation:
Table 48 Brand name/prescription products:
Table 49 Patent expiry data for approved formulation:
Table 50 Brand name/prescription products:
Table 51 Patent expiry data for approved formulation:
Table 52 Patent expiry data for approved formulation:
Table 53 Brand name/prescription products:
Table 54 Unapproved products:
Table 55 Patent expiry data for approved formulation:
Table 56 Brand name/prescription products:
Table 57 Generic products:
Table 58 Patent expiry data for approved formulation:
Table 59 Brand name/prescription products:
Table 60 Generic Products:
Table 61 Patent expiry data for approved formulation:
Table 62 Brand name/prescription products:
Table 63 Generic products:
Table 64 Patent expiry data for approved formulation:
Table 65 Brand name/prescription products:
Table 66 Brand name/prescription products:
Table 67 Patent expiry data for approved formulation:
Table 68 Brand name/prescription products:
Table 69 Brand name/prescription products:
Table 70 Patent expiry data for approved formulation:
Table 71 Brand name/prescription products:
Table 72 Patent expiry data for approved formulation:
Table 73 Brand name/prescription products:
Table 74 Generic Products:
Table 75 Combinations products:
Table 76 Patent expiry data for approved formulation:
Table 77 Brand name/prescription products:
Table 78 Patent expiry data for approved formulation:
Table 79 Combinations products:
Table 80 Patent expiry data for approved formulation:
Table 81 Brand name/prescription products:
Table 82 Patent expiry data for approved formulation:
Table 83 Brand name/prescription products:
Table 84 Combinations products:
Table 85 Opportunities for Generic Manufacturers
Table 86 Opportunities for Branded Manufacturers
Table 1 List of abbreviation
Table 2 List of data points generally requested by the Indian CMOs from Grand View Research Inc.
Table 3 India pharmaceutical manufacturing market revenue estimates and forecast, by dosage form, 2018 - 2030 (USD Million)
Table 4 India pharmaceutical manufacturing market revenue estimates and forecast, by manufacturing type, 2018 - 2030 (USD Million)
Table 5 India pharmaceutical manufacturing market revenue estimates and forecast, by therapeutic category, 2018 - 2030 (USD Million)
Table 6 Patent expiry data for approved formulation:
Table 7 Brand name/prescription products:
Table 8 Combinations products:
Table 9 Patent expiry data for approved formulation:
Table 10 Brand name/prescription products:
Table 11 Combinations products:
Table 12 Patent expiry data for approved formulation:
Table 13 Brand name/prescription products:
Table 14 Patent expiry data for approved formulation:
Table 15 Brand name/prescription products:
Table 16 Patent expiry data for approved formulation:
Table 17 Brand name/prescription products:
Table 18 Combinations products:
Table 19 Patent expiry data for approved formulation:
Table 20 Brand name/prescription products:
Table 21 Generic products:
Table 22 Combinations products:
Table 23 Patent expiry data for approved formulation:
Table 24 Brand name/prescription products:
Table 25 Generic products:
Table 26 Combination Products:
Table 27 Patent expiry data for approved formulation:
Table 28 Brand name/prescription products:
Table 29 Combinations products:
Table 30 Patent expiry data for approved formulation:
Table 31 Brand name/prescription products:
Table 32 Brand name/prescription products:
Table 33 Patent expiry data for approved formulation:
Table 34 Brand name/prescription products:
Table 35 Combinations products:
Table 36 Patent expiry data for approved formulation:
Table 37 Brand name/prescription products:
Table 38 Generic products:
Table 39 Combinations products:
Table 40 Patent expiry data for approved formulation:
Table 41 Brand name/prescription products:
Table 42 Generic products:
Table 43 Patent expiry data for approved formulation:
Table 44 Brand name/prescription products:
Table 45 Patent expiry data for approved formulation:
Table 46 Brand name/prescription products:
Table 47 Patent expiry data for approved formulation:
Table 48 Brand name/prescription products:
Table 49 Patent expiry data for approved formulation:
Table 50 Brand name/prescription products:
Table 51 Patent expiry data for approved formulation:
Table 52 Patent expiry data for approved formulation:
Table 53 Brand name/prescription products:
Table 54 Unapproved products:
Table 55 Patent expiry data for approved formulation:
Table 56 Brand name/prescription products:
Table 57 Generic products:
Table 58 Patent expiry data for approved formulation:
Table 59 Brand name/prescription products:
Table 60 Generic Products:
Table 61 Patent expiry data for approved formulation:
Table 62 Brand name/prescription products:
Table 63 Generic products:
Table 64 Patent expiry data for approved formulation:
Table 65 Brand name/prescription products:
Table 66 Brand name/prescription products:
Table 67 Patent expiry data for approved formulation:
Table 68 Brand name/prescription products:
Table 69 Brand name/prescription products:
Table 70 Patent expiry data for approved formulation:
Table 71 Brand name/prescription products:
Table 72 Patent expiry data for approved formulation:
Table 73 Brand name/prescription products:
Table 74 Generic Products:
Table 75 Combinations products:
Table 76 Patent expiry data for approved formulation:
Table 77 Brand name/prescription products:
Table 78 Patent expiry data for approved formulation:
Table 79 Combinations products:
Table 80 Patent expiry data for approved formulation:
Table 81 Brand name/prescription products:
Table 82 Patent expiry data for approved formulation:
Table 83 Brand name/prescription products:
Table 84 Combinations products:
Table 85 Opportunities for Generic Manufacturers
Table 86 Opportunities for Branded Manufacturers
LIST OF FIGURES
Fig. 1 India pharmaceutical manufacturing market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Dosage form and manufacturing type segment snapshot
Fig. 11 Therapeutic category segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Pharmaceuticals market value, 2023 (USD Million)
Fig. 14 Market dynamics
Fig. 15 India product flow
Fig. 16 Porter's Five Forces analysis
Fig. 17 PESTLE analysis
Fig. 18 India pharmaceutical manufacturing market: Product outlook and key takeaways
Fig. 19 India pharmaceutical manufacturing market: Dosage form movement analysis
Fig. 20 Penetration & growth prospect mapping for dosage form, 2023
Fig. 21 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Soft gelatin capsule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Hard gelatin capsules market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 India pharmaceutical manufacturing market: Manufacturing type outlook and key takeaways
Fig. 29 India pharmaceutical manufacturing market: Manufacturing type movement analysis
Fig. 30 Penetration & growth prospect mapping for manufacturing type, 2023
Fig. 31 In-house manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Advantages of in-house CRO & CMO
Fig. 33 Contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Contract manufacturing activities
Fig. 35 India pharmaceutical manufacturing market: Therapeutic category outlook and key takeaways
Fig. 36 India pharmaceutical manufacturing market: Therapeutic category movement analysis
Fig. 37 Penetration & growth prospect mapping for therapeutic category, 2023
Fig. 38 Endocrinology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Canagliflozin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Empagliflozin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Semaglutide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Tirzepatide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Linagliptin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Alogliptin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Trelagliptin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Myo-inositol market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Treprostinil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Azilsartan medoxomil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Azilsartan+Amlodipine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Amlodipine + Lisinopril market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Sparsentan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Esaxerenone market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 CNS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Cariprazine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Brexpiprazole market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Lisdexamfetamine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Vortioxetine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Mirogabalin besylate market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Lasmiditan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Siponimod market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Ibuprofen+Famotidine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Upadacitinib market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Antacid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Pantoprazole market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Antibiotic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Doxycycline market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Tedizolid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Antifungal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Posaconazole market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Antiprotozoal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Nitazoxanide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Lenalidomide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Daprodustat market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Roxadustat market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Edoxaban market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Avatrombopag market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Linaclotidemarket estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Apremilast market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Tegoprazan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Suvorexant market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Vonoprazan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Rolapitant market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Elagolix market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Global oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Oncology opportunities
Fig. 90 India injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Endocrinology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 CNS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Antacid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 Antibiotic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Antifungal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Antiprotozoal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 100 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 Intravenous market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 102 Subcutaneous market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Intramuscular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 104 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Company/competition categorization
Fig. 106 Key company market share analysis, 2023
Fig. 107 Strategy mapping
Fig. 1 India pharmaceutical manufacturing market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Dosage form and manufacturing type segment snapshot
Fig. 11 Therapeutic category segment snapshot
Fig. 12 Competitive landscape snapshot
Fig. 13 Pharmaceuticals market value, 2023 (USD Million)
Fig. 14 Market dynamics
Fig. 15 India product flow
Fig. 16 Porter's Five Forces analysis
Fig. 17 PESTLE analysis
Fig. 18 India pharmaceutical manufacturing market: Product outlook and key takeaways
Fig. 19 India pharmaceutical manufacturing market: Dosage form movement analysis
Fig. 20 Penetration & growth prospect mapping for dosage form, 2023
Fig. 21 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Soft gelatin capsule market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Hard gelatin capsules market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 India pharmaceutical manufacturing market: Manufacturing type outlook and key takeaways
Fig. 29 India pharmaceutical manufacturing market: Manufacturing type movement analysis
Fig. 30 Penetration & growth prospect mapping for manufacturing type, 2023
Fig. 31 In-house manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Advantages of in-house CRO & CMO
Fig. 33 Contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Contract manufacturing activities
Fig. 35 India pharmaceutical manufacturing market: Therapeutic category outlook and key takeaways
Fig. 36 India pharmaceutical manufacturing market: Therapeutic category movement analysis
Fig. 37 Penetration & growth prospect mapping for therapeutic category, 2023
Fig. 38 Endocrinology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Canagliflozin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Empagliflozin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Semaglutide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Tirzepatide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Linagliptin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Alogliptin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Trelagliptin market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Myo-inositol market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Treprostinil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Azilsartan medoxomil market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Azilsartan+Amlodipine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Amlodipine + Lisinopril market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Sparsentan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Esaxerenone market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 CNS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Cariprazine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 56 Brexpiprazole market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Lisdexamfetamine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Vortioxetine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Mirogabalin besylate market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 60 Lasmiditan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Siponimod market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Ibuprofen+Famotidine market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Upadacitinib market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Antacid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Pantoprazole market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Antibiotic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Doxycycline market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Tedizolid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Antifungal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Posaconazole market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Antiprotozoal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Nitazoxanide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Lenalidomide market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 76 Daprodustat market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Roxadustat market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 78 Edoxaban market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Avatrombopag market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 80 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 Linaclotidemarket estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 Apremilast market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 83 Tegoprazan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Suvorexant market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 85 Vonoprazan market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 Rolapitant market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 87 Elagolix market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Global oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 89 Oncology opportunities
Fig. 90 India injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 91 Endocrinology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 92 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 93 CNS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 94 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 95 Antacid market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 96 Antibiotic market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 97 Antifungal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 98 Antiprotozoal market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 99 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 100 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 101 Intravenous market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 102 Subcutaneous market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 103 Intramuscular market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 104 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 105 Company/competition categorization
Fig. 106 Key company market share analysis, 2023
Fig. 107 Strategy mapping
